Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selank
- Development stage
- Unknown
- Lead developer
- Institute of Molecular Genetics of the Russian Academy of Sciences
- Modality
- Peptides
- Administration
- Intranasal, Injectable
01
Overview
Selank is a synthetic heptapeptide (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a nootropic and anxiolytic drug. It is an analogue of the immunomodulatory peptide tuftsin, giving it immunomodulatory properties in addition to its central nervous system effects. Selank modulates neurotransmitter systems including GABAergic, serotonergic, and dopaminergic signaling, and also increases expression of brain-derived neurotrophic factor (BDNF). Research indicates it produces anxiolytic, antidepressant-like, cognitive-enhancing, and neuroprotective effects, with a favorable side effect profile lacking sedation or dependence[1][3][5][7]. It is approved for clinical use in Russia primarily for the treatment of anxiety and asthenic disorders, and is often used off-label for cognitive enhancement, stress resilience, and mental fatigue[1][5][7].
- Brand names
- Selank
- Other names
- Selank peptideSelankamidateSelankAcetateSelank peptidThr-Lys-Pro-Arg-Pro-Gly-ProTKPRPGP
02
Targets
BDNF (Brain-derived neurotrophic factor)DAT (Dopamine plasma membrane transport protein)ANPEP (Aminopeptidase N)GABRR (GABA-A receptor subunit rho)IL-6 (Interleukin 6)SERT (Sodium-dependent serotonin transporter)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on selank.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selank.